Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Beyond Air® To Participate in Three Upcoming Investor Conferences
LifeSci Partners HealthTech Symposium – September 20-21, 2022
Title: Beyond Air (XAIR) Fireside Chat
Date & Time: Wednesday, September 21, 2022, at 12:00 – 12:25pm ET
Moderator: Corey Davis, Ph.D., LifeSci Advisors, LLC
Participant: Steve Lisi, Chairman & CEO, Beyond Air
Location: Virtual
Webcast Link: Link
Ladenburg Thalmann Healthcare Conference – September 29, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, September 29, 2022, at 1:30pm – 1:55pm ET
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: Sofitel New York City
Webcast Link: Link
Roth Inaugural Healthcare Opportunities Conference – October 6, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, October 6, 2022, (Time - TBD)
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: The Yale Club, New York City
Webcast Link: TBD
https://stockhouse.com/news/press-releases/2022/09/16/beyond-air-xae-to-participate-in-three-upcoming-investor-conferences
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN. https://www.beyondair.net/news-and-events/press-releases/detail/153/beyond-air-provides-regulatory-update-for-lungfit-ph
How is nitric oxide stored in the human body?
Nitric oxide does not usually exist in its free form in the body due to its unstable nature but reacts with other molecules to form more stable products.
In the blood, nitric oxide has a very short half-life and rapidly oxidises to nitrite. It is then further oxidised with oxyhaemoglobin to produce nitrate. Nitric oxide also reacts directly with oxyhaemoglobin to produce methhaemoglobin and nitrate.
Reactions with cysteine residues in proteins lead to formation of nitrosylated products. Because of its high affinity to sulfhydryl groups (thiols), S-nitrosothiols (RSNOs) are the most common nitrosylated product in plasma.
Nitrate is the main storage form of nitric oxide. It is very stable when compared with other storage forms such as nitrites and RSNOs, which are important carriers and donor molecules of nitric
Beyond Air (XAIR) Investor Presentation - Slideshow
The following slide deck was published by Beyond Air, Inc. in conjunction with this event.
For further details see:
https://static.seekingalpha.com/uploads/sa_presentations/694/87694/original.pdf
Nitric Oxide will be the next Penicillin, the new safe antimicrobial solution to Antibiotic resistance and there are only a few companies working on it
I suggest you abandon your current trading strategy and try something new. Let me know if you are open to suggestions. GLTY
I just sold for loss and. It up
XAIR chart getting jiggy today. Hedge funds and institutions beginning to process this week's FDA approval news. My target is ~$20 before the end of this year. ~3x today's PPS. GLTY
https://stockcharts.com/h-sc/ui?s=XAIR&p=D&yr=0&mn=4&dy=0&id=p73405802842
Huge XAIR news after hours today!!!
FDA approval achieved!
https://www.beyondair.net/news-and-events/press-releases/detail/168/beyond-airs-lungfit-ph-receives-fda-approval-to-treat
This is a very under-the-radar stock. Not many institutions are following it yet. Mostly individual investors willing to take risk. Well risk-off as of today after hours with this announcement.
My guess is this stock will start moving up overnight tonight, but big moves may take days or weeks to arrive. It will take time for institutions to process this news, and begin to make sizable investments into a now FDA-approved Med Tech stock. My target is $20 before the end of the year. Might get there much sooner though. GLTY.
Time to start paying attention again. My guess is someone knows something about the pending FDA approval and is talking... GLTY
https://datadashboard.fda.gov/ora/firmprofile.htm?FEIs=3015861988
https://stockcharts.com/h-sc/ui?s=XAIR&p=D&yr=0&mn=4&dy=0&id=p47657378776
Just realized that the short interest
here is way too high, almost 10%. Will probably cash out on Monday.
% of shares Held by Institutions …….. 12.84
Short Interest % of Float (03/15/20) ……. 9.6
May have found a homerun in XSPA. Check it out. I am doubling up there on Monday in the AM.
AH is looking very good here.
This seems to go up, dip a bit at midday, and then settle down by close. You may want to wait until the midday dip tomorrow. Or, you may want to buy at the open as this may not dip. Loving this and AYTU. Hopeful for PCTL and DECN.
Hey good looking.
In addition to PCTL (which is really frustrating me), I'm adding XAIR and AYTU shares daily. Hopefully you didn't touch EWLL. What a horrible investment that is. DECN looks promising, but AYTU may have grabbed the quick 5-minute blood test market. When this is over, and the market starts roaring back, we can make a ton of $$$ with NYSE and NAZ stocks. I'm hoping to use the profits from the virus stocks to buy higher quality stocks.
Good volume. Looking to see continual
movement up from this point on. Waiting for the FDA ruling.
XAIR - Good morning boston!....Looks very interesting....
https://www.otcmarkets.com/stock/XAIR/news
https://web.tmxmoney.com/pricehistory.php?qm_symbol=XAIR:US
To a Good day,
janet
Looks like the possibility of FDA
fast-tracking the LungFit's application for trials on real patients is the reason for the move north. This is a great product that can be used for babies.
Nice move today and after hours.
Jumped into this today with a small BUY. Will follow closely.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36
|
Created
|
03/20/20
|
Type
|
Free
|
Moderators |
GARDEN CITY, N.Y., and REHOVOT, Israel, March 18, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, serious lung infections, including those suffering from COVID-19, and pulmonary hypertension, as well as gaseous NO for the treatment of solid tumors, today announced that the Company has drawn $5 million from its previously announced $25 million line of credit to provide the resources to more rapidly move the LungFit™™ BRO COVID-19 program forward.
“While we await feedback from BARDA (a division of HHS) and other US and international agencies, this money allows us to accelerate the anticipated COVID-19 clinical study start,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “While we anticipate receiving grants on an emergency basis, we have decided that there is an urgent need to commence the study as soon as possible pending IDE approval from FDA.
Beyond Air is an emerging medical device and biopharmaceutical company with groundbreaking technology. We are developing the LungFit™† platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders.
Our delivery system can generate up to 400 parts per million of nitric oxide for delivery to a patient's lung. It can deliver nitric oxide either continuously or intermittently with the ability to titrate on demand.
We believe the LungFit™ system satisfies a strong desire to eliminate cylinders from the hospital, providing significant benefits as a result. LungFit™ may be used anywhere in the hospital setting, providing the opportunity to treat infants with pulmonary hypertension and bronchiolitis. The simplicity and safety of the LungFit™ system may allow self-administration in the home, where we believe there is a high unmet need for patients with severe lung infections.
Beyond Air Inc. said Wednesday it will accelerate development of a medical device aimed to help treat patients with lung conditions that could include effects from Covid-19. Beyond Air said it drew $5 million from a $25 million line of credit to speed up progress on the device as it awaits government approvals for trials.
The device, LungFit, delivers nitric oxide to a patient's lungs. Previous trials have experimented with using nitric oxide to help patients with acute respiratory distress syndrome, which can be a result of Covid-19. Beyond Air says that LungFit could also be a treatment for pulmonary hypertension.
(RTTNews) - Beyond Air Inc. (XAIR) has a couple of clinical trial catalysts up its sleeve, making the stock worth watching in the coming months.
Beyond Air is a clinical-stage medical device and biopharmaceutical company developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension.
The lead investigational asset is LungFit PH, a next-generation phasic flow ventilator compatible nitric oxide delivery system. The cylinder free system is proposed for the treatment of pulmonary hypertension for certain ventilated patients in the hospital setting.
The Company is planning to seek FDA approval for LungFit PH next quarter (Q2, 2020). If all goes well as planned, the device may be launched in the fourth quarter of this year. The market potential of LungFit PH in the U.S. is estimated to be over $300 million.
Target Patient Population | US Sales Potential* | WW Sales Potential* | Launch Year*** |
Pulmonary Hypertension (in-hospital) | >$300m | >$600m | 2020 |
Bronchiolitis (in-hospital) | >$500m | >$1.2b | 2022 |
Severe Lung Infections (at-home)** | >$1b | >$2.5b | 2024 |
.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |